Scancell's SCIB1 Shows Promising Results in Phase 2 Melanoma Trial
• Scancell's SCIB1, combined with ipilimumab and nivolumab, demonstrates an 80% progression-free survival rate at 6 months in advanced melanoma patients.
• The SCOPE trial reports a 20% complete response rate and an 84% disease control rate among the 25 patients in cohort 1.
• These outcomes surpass reported results for double checkpoint inhibitors alone, indicating SCIB1's potential to enhance first-line therapy.
• Scancell is advancing SCIB1 and iSCIB1+ through clinical trials, with plans for a phase 2/3 randomized trial to support product registration.
Handheld Photoacoustic Scanner Offers Rapid, High-Resolution 3D Medical Imaging
• Researchers at UCL have developed a handheld photoacoustic tomography (PAT) scanner that generates detailed 3D images in seconds, a significant improvement over existing technology.
• The new scanner overcomes limitations of previous PAT devices by acquiring images 100 to 1,000 times faster, reducing motion-induced blurring and enabling real-time visualization of physiological events.
• Pre-clinical tests on patients with type-2 diabetes, rheumatoid arthritis, and breast cancer demonstrated the scanner's ability to visualize microvasculature and inflammation, offering potential for early disease detection.
• The technology could revolutionize medical understanding of biological processes and improve clinical assessment of cancer, peripheral vascular disease, and other major diseases.
Phase 1 Trial Shows Promise for Recurrent Glioblastoma with Targeted Radiopharmaceutical
• A Phase 1 clinical trial (CITADEL-123) at UCLH is evaluating ATT001, an Iodine-123 labelled PARP inhibitor, for recurrent glioblastoma, delivering targeted radioactivity to cancer cells.
• The first patient in the trial experienced a 50% reduction in tumor size following treatment with ATT001, showcasing the potential of Auger therapy.
• The trial utilizes an Ommaya reservoir for direct drug delivery to the tumor site after surgical resection, minimizing harm to healthy tissue.
• Ariceum Therapeutics sponsors the trial, marking the first clinical study of Auger therapy for recurrent glioblastoma, with plans for expansion cohorts and combination therapies.
Amivantamab and Lazertinib Combination Significantly Extends Progression-Free Survival in NSCLC
• A combination of amivantamab and lazertinib demonstrated a 40% improvement in halting lung cancer progression compared to standard treatment, offering new hope for patients.
• The Phase 3 trial involved over 1,000 patients with advanced non-small cell lung cancer (NSCLC), showing an average progression-free survival of 23.7 months with the drug combination.
• The treatment targets EGFR mutations, which are more prevalent in women and non-smokers, marking a significant advancement in precision medicine for lung cancer.
• FDA approved in August, this drug combination represents a crucial step forward, potentially improving survival rates and quality of life for lung cancer patients.
First Personalized mRNA Vaccine for Melanoma Enters UK Clinical Trials
• British patient Steve Young becomes one of the first to receive a groundbreaking personalized mRNA vaccine designed to prevent melanoma recurrence after surgical removal of tumors.
• The vaccine, mRNA-4157 (V940), is custom-built to match each patient's unique tumor genetic signature and works alongside immunotherapy drug pembrolizumab to help the immune system target remaining cancer cells.
• Phase III trials are underway across eight UK centers, aiming to recruit 60-70 patients, with experts suggesting this technology could potentially revolutionize treatment for melanoma and other cancers including lung, bladder, and kidney tumors.
© Copyright 2025. All Rights Reserved by MedPath